News >

ADCs and Other Novel Agents Boost HER2+ Breast Cancer Paradigm

Ellie Leick
Published: Thursday, Apr 09, 2020

Chau T. Dang, MD, the Regional Care Network Medical Site Director at Memorial Sloan Kettering Westchester

Chau T. Dang, MD

Several FDA approvals over the past year have propelled progress in HER2-positive breast cancer, and other novel agents are rapidly advancing through the pipeline, explained Chau T. Dang, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication